XTX Topco Ltd Acquires Shares of 34,968 Pulmonx Co. (NASDAQ:LUNG)

XTX Topco Ltd bought a new position in shares of Pulmonx Co. (NASDAQ:LUNG) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 34,968 shares of the company’s stock, valued at approximately $222,000.

Other hedge funds have also modified their holdings of the company. Sei Investments Co. boosted its position in Pulmonx by 2.5% during the first quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock worth $673,000 after acquiring an additional 1,800 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in Pulmonx by 7.0% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock worth $6,714,000 after purchasing an additional 69,595 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Pulmonx by 1.0% during the 2nd quarter. Victory Capital Management Inc. now owns 834,301 shares of the company’s stock worth $5,289,000 after purchasing an additional 8,004 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Pulmonx by 0.6% in the first quarter. Vanguard Group Inc. now owns 2,077,859 shares of the company’s stock valued at $19,262,000 after purchasing an additional 11,417 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Pulmonx by 609.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock valued at $79,000 after purchasing an additional 7,316 shares during the last quarter. 91.04% of the stock is currently owned by institutional investors and hedge funds.

Pulmonx Stock Up 0.4 %

Shares of NASDAQ:LUNG opened at $8.29 on Monday. The company has a market capitalization of $321.78 million, a price-to-earnings ratio of -5.38 and a beta of 0.63. Pulmonx Co. has a 12-month low of $5.46 and a 12-month high of $14.84. The business has a 50-day moving average price of $7.27 and a 200 day moving average price of $7.58. The company has a current ratio of 8.97, a quick ratio of 7.92 and a debt-to-equity ratio of 0.37.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings results on Wednesday, July 31st. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02. Pulmonx had a negative net margin of 75.56% and a negative return on equity of 50.79%. The business had revenue of $20.78 million during the quarter, compared to analysts’ expectations of $20.23 million. Sell-side analysts expect that Pulmonx Co. will post -1.64 EPS for the current year.

Insider Activity at Pulmonx

In other news, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $8.09, for a total transaction of $161,800.00. Following the completion of the transaction, the director now directly owns 1,111,974 shares in the company, valued at $8,995,869.66. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Pulmonx news, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $8.09, for a total value of $161,800.00. Following the completion of the transaction, the director now owns 1,111,974 shares of the company’s stock, valued at approximately $8,995,869.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Steven S. Williamson purchased 14,245 shares of Pulmonx stock in a transaction on Tuesday, August 20th. The stock was bought at an average cost of $6.84 per share, for a total transaction of $97,435.80. Following the transaction, the chief executive officer now directly owns 219,531 shares in the company, valued at $1,501,592.04. The disclosure for this purchase can be found here. In the last quarter, insiders sold 30,351 shares of company stock worth $231,094. Insiders own 5.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Wells Fargo & Company dropped their target price on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. Canaccord Genuity Group upped their price objective on shares of Pulmonx from $15.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Finally, Lake Street Capital started coverage on shares of Pulmonx in a report on Tuesday, June 4th. They issued a “buy” rating and a $12.00 target price on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $14.83.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.